Skip to main content

Market Overview

BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals

BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals

Ra Pharmaceuticals Inc (NASDAQ: RARX)'s lead drug, RA101495, could take about 15 percent of the refractory MG (Myasthenia Gravis) market, given the convenience of a daily subcutaneous administration, BMO Capital Markets’ Ian Somaiya said in a report. He initiated coverage of Ra Pharma with an Outperform rating and a price target of $26.

Ra Pharma offers investors “de-risked access to the multi-billion-dollar complement space,” which Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) seems to have “left open to competition,” Somaiya commented.

The Advantages

Ra Pharma’s lead drug is a low dose subcutaneous injection that can be self-administered. Moreover, its seven-day half-life provides coverage for missed doses and potentially weekly delivery.

“Pre-clinical and Phase 1 data suggest that RA101495 may provide more complete and sustained inhibition of C5 thus preventing breakthrough hemolysis observed in ~20 percent of patients managed on Soliris,” Somaiya wrote.

Although ALXN-1210 is better than Soliris, and Alexion is making advancements in subcutaneous ALXN-1210. The analyst pointed out, however, that the volume of drug required may impact convenience, allowing Ra Pharma’s lead drug to gain market share, “especially in a single payor environment where discounted pricing could lead to active switching.”

Ra Pharma went public with an IPO on the NASDAQ in October.

Latest Ratings for RARX

Nov 2019Guggenheim SecuritiesDowngradesBuyNeutral
Nov 2019Stifel NicolausDowngradesBuyHold
Oct 2019Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for RARX
View the Latest Analyst Ratings


Related Articles (RARX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at